CELG
Celgene Corporation
Last Trade: 122.58%Change: -0.86%
Current Volume: 2286520
CELG is currently neutral.
P/E: 37.61Market Cap: 51.131B
52 Week High: 128.52
52 Week Low: 58.53
Next Year EPS: 6.90
getbillasap
$CELG weekly $125s expired worthless from .15. Bot Jun 100s at 22.25 earlier in day. weekly 120s sold at 2.35 from 3.9. crappy
thetapositive
@Tony_BATtista #tastyidea $CELG High.IV% selling 120/125 strangle for 6.37
COCKRELLGROUP
Wells Fargo analyst Brian Abrahams increased his valuation range of Celgene $CELG to 139 - $141 from $137 - $139.
pdm1010
RT @CreateCapital: There is so much new $CELG money in Morris County that its sick. They gave everybody options/RSUs
CreateCapital
There is so much new $CELG money in Morris County that its sick. They gave everybody options/RSUs
AndyLewis5
3 stop $CELG JUNE 125 triggered for -28%
GOOG AAPL AMZN NFLX CELG COST AMGN WFM TSLA LIFE QQQ GMCR ILMN ADP PETM VIAB BBBY
MDY IBM V LNKD SPG IVV SPY GS UNP DIA PXD GLD EOG ACT CVX LQD NBL TIP CMI TLT
New Highs! BA TSLA PG JAZZ SLXP STZ PXP BMY TRI ALKS SAVE BR EA CVA SCI P WEN
MDY IBM V LNKD SPG IVV SPY GS UNP DIA PXD GLD EOG ACT CVX LQD NBL TIP CMI TLT
New Highs! BA TSLA PG JAZZ SLXP STZ PXP BMY TRI ALKS SAVE BR EA CVA SCI P WEN
| CELG is currently neutral. |
|
Watchlist:
CVX IJH NBL WHR MDY RL VFC SPG IVV SPY PSA GS UNP PPG DIA PXD WYNN BLK BIIB ACT BA DOV FMC WDC SNPS LPS HPQ P BR FRX ALKS DPZ
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. Its primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.
UK_LBN
 |